Drug intelligence / Profile preview

AtoKin

Development stage: Unknown
Lead developer: Elanco
Modality: Small Molecules
Administration: Oral

Overview

**AtoKin** is a beef-flavored, chewable formulation of a high-dose, second-generation histamine H1-receptor antagonist developed by Kindred Bio for veterinary use in dogs. It acts as an antihistamine that does not cross the blood-brain barrier, reducing drowsiness and side effects compared to first-generation agents. The active ingredient, extensively studied in humans for allergic rhinitis, demonstrated efficacy in a peer-reviewed study on canine atopic dermatitis, showing comparability to methylprednisolone at 3 weeks and superior efficacy at 6 weeks.[1][3]

Brand names: AtoKin

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on AtoKin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AtoKin.

Explore the full profile